Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.

Rev Assoc Med Bras (1992)

Associação Médica Brasileira, Medicina Baseada em Evidências - São Paulo (SP), Brazil.

Published: January 2022

Download full-text PDF	Source
http://dx.doi.org/10.1590/1806-9282.2022D681	DOI Listing

Publication Analysis

disease-modifying drugs

drugs tocilizumab

tocilizumab tofacitinib

tofacitinib baricitinib-a

baricitinib-a biological

biological synthetic

synthetic target

target specific

specific patients

patients hospitalized

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!